Lance Smith, Author at Clinical Trial Recruitment

Tilray® Supports New Clinical Trial Evaluating the Efficacy of Medical Cannabis in Disorders Caused by Breast Cancer Treatment

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

First-of-its-kind trial will test the efficacy of cannabis as a treatment for taxane-induced peripheral neuropathy, which affects 67 percent of women undergoing breast cancer treatment NANAIMO, British Columbia–(BUSINESS WIRE)–Tilray, Inc. (NASDAQ: TLRY),...

SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the...

First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda’s Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Positive findings on clinical endpoints for Budesonide Oral Suspension (BOS) presented during ACG 2019 Presidential Plenary Session LEXINGTON, Mass., Oct. 28, 2019 /PRNewswire/ — Takeda Pharmaceuticals U.S.A., Inc., (“Takeda”)...

MedRhythms Initiates Multi-Site Randomized Controlled Trial at the Nation’s Top Rehab Hospitals for Its Post-Stroke Walking Rehabilitation Device

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

5-Center Study of the Device is Intended to Provide Clinical Data in Support of MedRhythms’ FDA Submission. PORTLAND, Maine–(BUSINESS WIRE)–MedRhythms, Inc., a Portland, Maine-based digital therapeutics company, today announced the launch of its 5-site...

NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

by Lance Smith | Oct 28, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring...

« Older Entries

Next Entries »